

15 April 2025

Argent BioPharma Ltd.
(Argent BioPharma or the Company)

Argent BioPharma and AusCann Enter into Strategic Heads of Agreement to Enhance Cannabinoid Drug Development

Highlights:

- **Argent BioPharma and AusCann have entered into a Strategic Heads of Agreement to accelerate cannabinoid-based pharmaceutical development.**
- **The collaboration will leverage each company's proprietary datasets and regulatory expertise to streamline regulatory submissions and enhance market readiness.**
- **AusCann will license Argent BioPharma's CannEpi[®] CMC and Dossier for non-epilepsy related pharmaceutical programs, ensuring no competition with Argent's existing epilepsy-focused product portfolio.**
- **Both companies gain access to pharmacokinetic (PK) and pharmacodynamic (PD) data from Neuvis[®]—AusCann's self-emulsifying hard-shell capsule formulation.**
- **Establishment of a Joint Steering Committee (JSC) to coordinate R&D efforts and optimize regulatory strategies.**
- **Agreement incorporates a deferred licensing fee structure with royalties on future pharmaceutical products.**

Argent BioPharma (ASX: RGT), a clinical-stage biopharmaceutical company, and AusCann Group Holdings Ltd (AusCann) are pleased to announce the signing of a Strategic Heads of Agreement aimed at advancing cannabinoid-based pharmaceutical development through the synergistic exchange of proprietary datasets and regulatory expertise.

Under this agreement, AusCann will license Argent BioPharma's CannEpi[®] CMC and Dossier specifically for non-epilepsy related pharmaceutical programs. CannEpi[®], Argent's flagship cannabinoid-based therapy for refractory epilepsy, is recognized for its innovative approach in neuroimmune modulation and cannabinoid therapeutics. This licensing agreement ensures no competition with Argent's epilepsy-focused portfolio while allowing AusCann to enhance its own programs with Argent's proven regulatory and clinical frameworks.

Additionally, both companies will gain access to Neuvis[®], AusCann's proprietary self-emulsifying hard-shell capsule formulation, including PK and PD data that has demonstrated improved stability, bioavailability, and scalable manufacturing potential. This mutual exchange aims to accelerate drug development timelines, enhance regulatory submissions, and improve market readiness for cannabinoid-based therapeutics.

Agreement Framework:

1. **Mutual Data Exchange and Licensing:**
 - a. Both companies will access PK and PD data from Neuvis[®], AusCann's innovative self-emulsifying hard-shell capsule formulation.
 - b. AusCann will license Argent's CannEpi[®] CMC and Dossier for use in non-epilepsy related pharmaceutical programs only.
2. **Joint Steering Committee:**
 - a. A Joint Steering Committee (JSC) with representatives from both companies will be formed to oversee R&D efforts, optimize data utilisation, and streamline regulatory pathways.

3. Financial Structure & Value Creation:

- a. The agreement features a deferred licensing fee structure, with royalties on pharmaceutical products developed using jointly leveraged data, R&D, or assets.
- b. The collaboration aims to reduce regulatory development costs, accelerate timelines, and enhance access to preclinical and clinical data.

Strategic Partnership for Future Growth

By combining regulatory expertise, proprietary data, and pharmaceutical assets, this Heads of Agreement lays the groundwork for a robust, long-term strategic partnership. Both Argent BioPharma and AusCann aim to unlock new opportunities in cannabinoid-based pharmaceutical development while ensuring mutual value creation and streamlined regulatory advancement.

Roby Zomer, Chairman of Argent BioPharma:

"This strategic agreement with AusCann is a major validation of the value we've created through years of focused investment in the CannEpi® program. By licensing our CMC and regulatory dossier for non-epilepsy indications, we're unlocking new revenue streams while maintaining the integrity of our epilepsy portfolio. The integration of our proprietary data into AusCann's development pipeline demonstrates the real-world utility and market relevance of our scientific work. This collaboration marks a significant step forward in Argent BioPharma's strategy to capitalise on our intellectual assets and extend our leadership in cannabinoid-based therapeutics."

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Limited (ASX: RGT) is an innovative clinical-stage biopharmaceutical company specialising in neuroimmunology and advanced nanomedicine. By leveraging the Neuro-Immune Modulatory (NIM) System, Argent BioPharma's robust pipeline—including CannEpi®, CogniCann®, and CimetrA®—targets CNS disorders and immune-related conditions. With a commitment to science-driven innovation, Argent BioPharma is shaping the future of cannabinoid-based therapeutics and neuroimmune modulation.

Follow us through our social media channels:

LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma

About AusCann Group Holdings Limited

AusCann is an Australian-based company focused on the development and commercialisation of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. Our key difference is the commitment to rigorous product development, focused on providing reliable, stable and standardised cannabinoid-derived therapeutics products, whilst generating robust safety, quality assurance and efficacy data to support market access in various regulatory environments around the world.

Argent BioPharma Ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 info@argentbiopharma.com